Topical beremagene geperpavec

Phase 3

Krystal Biotech, Inc. (KRYS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Dystrophic Epidermolysis Bullosa

View Full Landscape

Drug Information

Target Indication

Dystrophic Epidermolysis Bullosa

Clinical Trial

NCT03536143

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/23/2025

Vyjuvek

Vyjuvek is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene, from birth

OrphanPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

KRYS

Krystal Biotech, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Open Label Topical Beremagene Geperpavec (B-VEC)Phase 3

Dystrophic Epidermolysis Bullosa

KB803Phase 3

Dystrophic Epidermolysis Bullosa

KB801Phase 2

Neurotrophic Keratitis

KB707Phase 2

Lung Cancer, Non-small Cell

OpdualagPhase 2

Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts